Crossmark

Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar)

Crossref DOI link: https://doi.org/10.1007/s11739-020-02386-0

Published Online: 2020-06-10

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vacchi, Caterina

Visentini, Marcella

Gragnani, Laura

Fraticelli, Paolo

Tavoni, Antonio

Filippini, Davide

Saccardo, Francesco

Lauletta, Gianfranco

Colantuono, Stefania

Atzeni, Fabiola

Pioltelli, Pietro

Manfredi, Andreina

Casato, Milvia

Zignego, Anna Linda

Monti, Giuseppe

Pietrogrande, Maurizio

Galli, Massimo

Sebastiani, Marco
License Information

Text and Data Mining valid from 2020-06-10

Version of Record valid from 2020-06-10
More Information

Article History

Received: 10 March 2020

Accepted: 27 May 2020

First Online: 10 June 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

: Informed consent was obtained from all patients for being included in the study.

Document is current

Any future updates will be listed below